Stevens-Johnson syndrome and toxic epidermal necrolysis
References
Key articles
Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993 Jan;129(1):92-6. Abstract
Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016 Jun;174(6):1194-227.Full text Abstract
Seminario-Vidal L, Kroshinsky D, Malachowski SJ, et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. J Am Acad Dermatol. 2020 Jun;82(6):1553-67. Abstract
Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016 Aug;123(8):1653-8. Abstract
Reference articles
1. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child. 1922 Dec;24(6):526-33.
2. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015 Dec;16(6):475-93. Abstract
3. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993 Jan;129(1):92-6. Abstract
4. Charlton OA, Harris V, Phan K, et al. Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review. Adv Wound Care (New Rochelle). 2020 Jul;9(7):426-39.Full text Abstract
5. Hsu DY, Brieva J, Silverberg NB, et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017 May;76(5):811-7.Full text Abstract
6. Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017 Jun;137(6):1240-7.Full text Abstract
7. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013 May;133(5):1197-204.Full text Abstract
8. Gillis NK, Hicks JK, Bell GC, et al. Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort. J Invest Dermatol. 2017 Sep;137(9):2021-3.Full text Abstract
9. Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993 Jun 10;328(23):1670-4.Full text Abstract
10. Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012 Feb 1;13(1):49-54. Abstract
11. Yip VL, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol. 2015 Jun;48(2-3):165-75. Abstract
12. Chang CC, Too CL, Murad S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011 Feb;50(2):221-4. Abstract
13. Chung WH, Hung SI. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010 Dec;59(4):325-32.Full text Abstract
14. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013 Sep;94(3):324-8.Full text Abstract
15. Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015 Jun;135(6):1538-45. Abstract
16. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013 Feb;93(2):153-8.Full text Abstract
17. Kongpan T, Mahasirimongkol S, Konyoung P, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015 Aug;25(8):402-11. Abstract
18. Tangamornsuksan W, Lohitnavy O, Kongkaew C, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18(1):68-76.Full text Abstract
19. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994 Nov 10;331(19):1272-85. Abstract
20. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002 Aug;138(8):1019-24. Abstract
21. Nethercott JR, Choi BC. Erythema multiforme (Stevens Johnson syndrome) chart review of 123 hospitalized patients. Dermatologica. 1985;171(6):383-96. Abstract
22. Centers for Disease Control and Prevention. Smallpox: vaccine adverse events. 2016 [internet publication].Full text
23. Morantz C. CDC releases guidelines for treating adverse reactions to smallpox vaccination. Am Fam Physician. 2003 Apr 15;67(8):1827, 1829-30.Full text Abstract
24. Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014 Mar;33(1):10-6. Abstract
25. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995 Dec 14;333(24):1600-7.Full text Abstract
26. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002 Nov;63(11):1012-9. Abstract
27. Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009 Feb;123(2):e297-304. Abstract
28. Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83(1):1-9. Abstract
29. Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008 Nov;62(5):879-88.Full text Abstract
30. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28(10):917-24. Abstract
31. Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29(8):687-96. Abstract
32. Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013 Feb;149(2):152-8.Full text Abstract
33. Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8(6):681-92.
34. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. J Invest Dermatol. 2008 Jan;128(1):35-44.Full text Abstract
35. Irazabal MP, Martin LM, Gil LA, et al. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013 Mar;47(3):e16. Abstract
36. Tremblay L, de Chambrun GP, De Vroey B, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis. 2011 Oct;5(5):457-60.Full text Abstract
37. Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014 Feb;25(2):225-34.Full text Abstract
38. Mawson AR, Eriator I, Karre S. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role? Med Sci Monit. 2015 Jan 12;21:133-43.Full text Abstract
39. Chen CB, Wu MY, Ng CY, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10:1259-73.Full text Abstract
40. Paul C, Wolkenstein PC, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996 Apr;134(4):710-4. Abstract
41. Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000 Jan;119(1):225-30.Full text Abstract
42. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013 Aug;69(2):173. Abstract
43. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2006 Oct;155(4):722-8. Abstract
44. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013 Aug;69(2):187. Abstract
45. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998 Oct 16;282(5388):490-3. Abstract
46. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008 Dec;14(12):1343-50. Abstract
47. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003 May;162(5):1515-20.Full text Abstract
48. Hama N, Nishimura K, Hasegawa A, et al. Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2894-7. Abstract
49. Hasegawa A, Shinkuma S, Hayashi R, et al. RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol Pract. 2020 May;8(5):1768-71. Abstract
50. Ziemer M, Kardaun SH, Liss Y, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012 Mar;166(3):575-600. Abstract
51. Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. Am J Clin Oncol. 2014 Oct;37(5):506-13. Abstract
52. Demiral AN, Yerebakan O, Simsir V, et al. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report. Jpn J Clin Oncol. 2002 Nov;32(11):477-9.Full text Abstract
53. Jorge J, Kowal-Vern A, Fung HCH, et al. Toxic epidermal necrolysis and graft versus host disease after hematopoietic and liver transplantation: a review. Int J Clin Expl Dermatol. 2018 Sep 27;3(1):1-9.Full text
54. de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med. 2014 Jan;42(1):118-28. Abstract
55. Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obst. 1944;79:352-8.
56. Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004 Jul 10;329(7457):101-3.Full text Abstract
57. Wachtel TL, Berry CC, Wachtel EE, et al. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns. 2000 Mar;26(2):156-70. Abstract
58. Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson Syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011 Mar-Apr;32(2):237-45. Abstract
59. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006 Feb;126(2):272-6.Full text Abstract
60. Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res. 2008 Jan-Feb;29(1):141-6. Abstract
61. George SM, Harrison DA, Welch CA, et al. Dermatological conditions in intensive care: a secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) case mix programme database. Crit Care. 2008;12(suppl 1):S1.Full text Abstract
62. Imahara SD, Holmes JH, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006 May-Jun;27(3):270-5. Abstract
63. Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016 Jun;174(6):1194-227.Full text Abstract
64. Kowal-Vern A, Walenga JW, Hoppensteadt D, et al. Patients with Stevens-Johnson syndrome and toxic epidermal necrolysis develop coagulopathies similar to those seen in burn patients: a pilot study. Int J Clin Expl Dermatol. 2018 Sep 27;3(1):1-9.Full text
65. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013 May;68(5):693. Abstract
66. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol. 2013 May;68(5):709. Abstract
67. Baba M, Karakas M, Aksunger VL, et al. The anticonvulsant hypersensitivity syndrome. J Eur Acad Dermatol Venereol. 2003 Jul;17(4):399-401. Abstract
68. Centers for Disease Control and Prevention. Toxic syndrome description: vesicant/blister agent poisoning. Apr 2018 [internet publication].Full text
69. Sehgal V, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol. 2006 Aug;45(8):897-908. Abstract
70. Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013 Apr;168(4):726-32. Abstract
71. Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:260928.Full text Abstract
72. Chung WH, Shih SR, Chang CF, et al. Clinicopathologic analysis of coxsackievirus A6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013 Dec 15;208(12):1968-78.Full text Abstract
73. Garg T, Sanke S, Ahmed R, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis-like cutaneous presentation of chikungunya fever: a case series. Pediatr Dermatol. 2018 May;35(3):392-6. Abstract
74. Seminario-Vidal L, Kroshinsky D, Malachowski SJ, et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. J Am Acad Dermatol. 2020 Jun;82(6):1553-67. Abstract
75. Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017 Jun 1;153(6):514-22.Full text Abstract
76. Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017 Jun;34(6):1235-44.Full text Abstract
77. Nizamoglu M, Ward JA, Frew Q, et al. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: a regional burns centre experience. Burns. 2018 May;44(3):603-11. Abstract
78. Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010 Jan-Feb;31(1):100-4. Abstract
79. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015 Jan;54(1):108-15. Abstract
80. Aires DJ, Fraga G, Korentager R, et al. Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol. 2013 Jun 1;12(6):679-84. Abstract
81. Enk A, Hadaschik E, Eming R, et al. European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Dtsch Dermatol Ges. 2017 Feb;15(2):228-41. Abstract
82. Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014 Nov;71(5):941-7. Abstract
83. Balai M, Meena M, Mittal A, et al. Cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis: experience from a tertiary care centre of South Rajasthan. Indian Dermatol Online J. 2021 Jan-Feb;12(1):116-22.Full text Abstract
84. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010 Oct;163(4):847-53. Abstract
85. Ng QX, De Deyn MLZQ, Venkatanarayanan N, et al. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. J Inflamm Res. 2018 Mar 28;11:135-42.Full text Abstract
86. González-Herrada C, Rodríguez-Martín S, Cachafeiro L, et al. Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol. 2017 Oct;137(10):2092-100.Full text Abstract
87. Roujeau JC, Mockenhaupt M, Guillaume JC, et al. New evidence supporting cyclosporine efficacy in epidermal necrolysis. J Invest Dermatol. 2017 Oct;137(10):2047-9.Full text Abstract
88. Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016 Aug;123(8):1653-8. Abstract
89. Van Batavia JP, Chu DI, Long CJ, et al. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Pediatr Urol. 2017 Oct;13(5):490.e1-7. Abstract
90. Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol. 1998 Feb;91(2):283-7. Abstract
91. Gupta LK, Martin AM, Agarwal N, et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: an Indian perspective. Indian J Dermatol Venereol Leprol. 2016 Nov-Dec;82(6):603-25.Full text Abstract
92. Zhang S, Tang S, Li S, et al. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. J Dermatolog Treat. 2020 Feb;31(1):66-73. Abstract
93. Paradisi A, Abeni D, Didona D, et al. A new case series on etanercept treatment for toxic epidermal necrolysis. Eur J Dermatol. 2020 Oct 1;30(5):561-8. Abstract
94. Zhang J, Lu CW, Chen CB, et al. Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study. J Allergy Clin Immunol Pract. 2022 May;10(5):1295-304. Abstract
95. Satake Y, Higa K, Tsubota K, et al. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. Ophthalmology. 2011 Aug;118(8):1524-30. Abstract
96. Sotozono C, Inatomi T, Nakamura T, et al. Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. Acta Ophthalmol. 2014 Sep;92(6):e447-53.Full text Abstract
97. Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011 Oct;128(4):723-8. Abstract
98. Del Pozzo-Magaña BR, Lazo-Langner A. Stevens Johnson Syndrome and toxic epidermal necrolysis in children: a literature review of current treatments. EMJ Dermatol. 2016 Nov;4(1):83-9.Full text
99. Singalavanija S, Limpongsanurak W. Stevens-Johnson syndrome in Thai children: a 29-year study. J Med Assoc Thai. 2011 Aug;94(suppl 3):S85-90. Abstract
100. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002 Mar-Apr;23(2):87-96. Abstract
101. Wakamatsu TH, Ueta M, Tokunaga K, et al. Human leukocyte antigen class I genes associated with Stevens-Johnson syndrome and severe ocular complications following use of cold medicine in a Brazilian population. JAMA Ophthalmol. 2017 Apr 1;135(4):355-60.Full text Abstract
102. Jeschke MG, Finnerty CC. The hepatic response to a thermal injury. In: Herndon DN, ed. Total burn care. 4th ed. Philadelphia, PA: Elsevier; 2012:301-12.
103. Goverman J, Fagan SP. Renal failure in association with thermal injuries. In: Herndon, DN, ed. Total burn care. 4th ed. Philadelphia, PA: Elsevier; 2012:369-76.
104. Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011 Summer;4(2):81-5.Full text Abstract
105. Kamada N, Kinoshita K, Togawa Y, et al. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro/SS-A and a review of the published work. J Dermatol. 2006 Sep;33(9):616-22. Abstract
106. Baccaro LM, Sakharpe A, Miller A, et al. The first reported case of ureteral perforation in a patient with severe toxic epidermal necrolysis syndrome. J Burn Care Res. 2014 Jul-Aug;35(4):e265-8. Abstract
Use of this content is subject to our disclaimer